Sana Biotechnology will present preclinical data for its CD19-targeted in vivo CAR T candidate SG293 at the ASGCT 2026 meeting, showcasing a targeted delivery platform. The news coincides with Janux ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...
Key manufacturing milestone follows Tempest’s recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% complete response in all six efficacy ...
Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options. The introduction of CD19 ...
Add Yahoo as a preferred source to see more of our stories on Google. LBCL continues to present major clinical challenges despite improvements with chemoimmunotherapy. Credit: SVStocker via ...
Schematic illustration explaining the working principle of BCMA-CD19 bispecific CAR T cells used in current study. CD19 is the pan B cell marker but not expressed in long-lived plasma cells and BCMA ...
The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SYDNEY & DUARTE, Calif.--(BUSINESS WIRE)--Imugene Ltd (ASX:IMU), an immuno-oncology company and City of Hope, a world-renowned independent cancer research and treatment center near Los Angeles, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results